In the vast landscape of the pharma industry, a narrative akin to the biblical tale of David and Goliath often unfolds. On one side stand the industry’s behemoths, the Big Pharma companies with deep pockets, extensive resources, and established market dominance. The smaller, agile biotech firms are on the other side, armed with innovation, creativity, and a hunger to disrupt the status quo. The question arises: Can these small biotechs genuinely compete against the giants of the pharma world?